Scripps study claims rebate system does inflate drug prices

Pharmaphorum

3 June 2019 - The pharma industry has been claiming for years that the rebate system is a key factor in driving price increases in the US. Now, a study by Scripps Research provides evidence to support that view.

The non-profit scientific institute analysed tens of millions of insurance claims for the top 49 pharmaceutical brands in the US and found “continual, marked, annual increases” that drive up prices by a median of 76% between January 2012 and December 2017.

The study – published in JAMA Network Open – found that 78% of 36 drugs available over the entire study period saw an increase in insurer and out-of-pocket costs of more than 50%, while 44% more than doubled in price.

Read Pharmaphorum article

Michael Wonder

Posted by:

Michael Wonder